Taysha Gene Therapies (NASDAQ:TSHA) Given New $15.00 Price Target at Robert W. Baird

Posted by George Bondi on Jun 30th, 2026

Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report) had its price target increased by investment analysts at Robert W. Baird from $12.00 to $15.00 in a research note issued on Tuesday,Benzinga reports. The firm currently has an “outperform” rating on the stock. Robert W. Baird’s target price indicates a potential upside of 122.88% from the stock’s current price.

Other research analysts also recently issued reports about the company. Bank of America lifted their price target on Taysha Gene Therapies from $9.00 to $10.00 and gave the company a “buy” rating in a report on Monday, June 22nd. Canaccord Genuity Group upped their price objective on Taysha Gene Therapies from $14.00 to $17.00 and gave the stock a “buy” rating in a research note on Monday, April 6th. Chardan Capital reaffirmed a “buy” rating and set a $12.00 price objective on shares of Taysha Gene Therapies in a research report on Thursday, March 19th. Truist Financial upgraded Taysha Gene Therapies to a “strong-buy” rating in a research note on Wednesday, March 25th. Finally, BMO Capital Markets boosted their target price on shares of Taysha Gene Therapies from $10.00 to $14.00 and gave the stock an “outperform” rating in a report on Tuesday, June 23rd. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $12.62.

View Our Latest Stock Report on Taysha Gene Therapies

Taysha Gene Therapies Price Performance

NASDAQ TSHA opened at $6.73 on Tuesday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 14.04 and a current ratio of 14.04. The firm’s 50 day moving average price is $6.13 and its 200-day moving average price is $5.30. Taysha Gene Therapies has a 52-week low of $2.25 and a 52-week high of $7.30. The company has a market cap of $1.93 billion, a PE ratio of -17.71 and a beta of 1.19.

Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.02). Sell-side analysts forecast that Taysha Gene Therapies will post -0.5 EPS for the current fiscal year.

Insider Transactions at Taysha Gene Therapies

In other news, insider Sukumar Nagendran sold 200,000 shares of the company’s stock in a transaction on Friday, April 10th. The stock was sold at an average price of $4.46, for a total transaction of $892,000.00. Following the transaction, the insider directly owned 1,136,410 shares of the company’s stock, valued at approximately $5,068,388.60. This represents a 14.97% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 3.78% of the company’s stock.

Institutional Trading of Taysha Gene Therapies

A number of institutional investors have recently made changes to their positions in the business. Marex Group plc acquired a new position in Taysha Gene Therapies during the 2nd quarter valued at about $29,000. E Fund Management Co. Ltd. purchased a new stake in shares of Taysha Gene Therapies during the second quarter worth about $31,000. Arrowpoint Investment Partners Singapore Pte. Ltd. purchased a new stake in shares of Taysha Gene Therapies during the third quarter worth about $40,000. Tower Research Capital LLC TRC increased its holdings in shares of Taysha Gene Therapies by 156.5% during the second quarter. Tower Research Capital LLC TRC now owns 17,606 shares of the company’s stock valued at $41,000 after acquiring an additional 10,742 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd increased its holdings in shares of Taysha Gene Therapies by 143.8% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 7,811 shares of the company’s stock valued at $43,000 after acquiring an additional 4,607 shares in the last quarter. Institutional investors and hedge funds own 77.70% of the company’s stock.

Taysha Gene Therapies Company Profile

(Get Free Report)

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.